INDICATIONS

RINVOQ is indicated for the treatment of adults with:

• Moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
• Moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biological therapies for Crohn’s disease or ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine.